SCHEMBL3012415

SCHEMBL3012415

Cc1cc(S(=O)(=O)C2CCN(c3nc(-c4cc(F)cc(F)c4)cs3)CC2)c(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.44
SMN1; SMN2 Q16637 8/20 0.44
ALDH1A1 P00352 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
MAPT P10636 4/20 0.41
LMNA P02545 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CTSS P25774 2/20 0.37
AR P10275 3/20 0.37
HTT P42858 2/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018924 0.95 MAPK1 (0.42) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3008704 0.91 SMN1; SMN2 (0.45) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3019957 0.90 SMN1; SMN2 (0.42) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3006833 0.89 MAPK1 (0.45) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3010363 0.88 MAPK1 (0.45) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3015148 0.88 MAPK1 (0.45) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3018331 0.87 SMN1; SMN2 (0.53) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL2998403 0.87 SMN1; SMN2 (0.49) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3015907 0.87 LMNA (0.54) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3018871 0.87 SMN1; SMN2 (0.53) MAPK1SMN1; SMN2ALDH1A1L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.